Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 2,290 trials in your specialties ()
View trials across your selected specialties

Healthy Summer Learners

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Overweight and Obesity, Academic Acheivement
View Full Trial
INTERVENTION

Behavioral: Healthy Summer Learners, Behavioral: 21st Century Summer Learning Center

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of South Carolina, Columbia, South Carolina, United States

Brief Summary

Summer vacation represents a "window of vulnerability" where dramatic declines in both health and academics occur for elementary age children. Currently, there are no summer programs that incorporate curriculum addressing both unhealthy weight gains and academic achievement simultaneously. This work represents an important step towards addressing important public health goals - obesity and learning - through a comprehensive program delivered during a timeframe - summer vacation - where substantial and long-lasting negative effects occur.

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma,...
View Full Trial
INTERVENTION

Drug: TAK-659, Drug: Venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1 prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when administered in combination.

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Myelomonocytic Leukemia
View Full Trial
INTERVENTION

Drug: Ruxolitinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Brief Summary

The purpose of this study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug [ruxolitinib] can improve outcomes of patients with CMML. The first step of the study is to learn the dose of ruxolitinib that is tolerable (bearable). It has already been studied in a number of patients with different bone marrow diseases and is approved for the treatment of a disease called Myelofibrosis; however, it is not approved for treatment of CMML. It is given orally (by mouth). Most people tolerate it well but the tolerability has not been determined in patients with CMML. We will be testing different doses to determine how much of the medication people can tolerate (bear) before they develop side effects.

A Study of LY3023414 in Participants With Advanced Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, ...
View Full Trial
INTERVENTION

Drug: LY3023414, Drug: Midazolam, Drug: Fulvestrant, Drug: Pemetrexed, Drug: Cisplatin, Drug: Abemaciclib, Drug: Letrozole

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UCLA Medical Center, Los Angeles, California, United States

Brief Summary

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refracto...
View Full Trial
INTERVENTION

Biological: BinD19

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Children's Hospital of Fudan University, Shanghai, Shanghai, China

Brief Summary

This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in childhood patients with B-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr ...
View Full Trial
INTERVENTION

Biological: tabelecleucel, Biological: pembrolizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope, Duarte, California, United States

Brief Summary

This is a multicenter, open-label, single-arm phase 1b/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-C...
View Full Trial
INTERVENTION

Radiation: External beam radiation (dose level 2), Drug: Durvalumab, Drug: Tremelimumab, Drug: Cisplatin (dose level 4), Drug: Cisplatin (dose level 3), Drug: Carboplatin (dose level 1), Drug: Carboplatin (dose level 2), Drug: Etoposide (dose level 1), Drug: Etoposide (dose level 2), Drug: Paclitaxel, Drug: Pemetrexed, Radiation: External beam radiation (dose level 1), Radiation: External beam radiation (hyperfractionated), Drug: Cisplatin (dose level 1), Drug: Cisplatin (dose level 2), Radiation: External beam radiation (standard)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Tucson, Arizona, United States

Brief Summary

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

A Study of Ad26.COV2.S in Adults (COVID-19)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Healthy
View Full Trial
INTERVENTION

Biological: Ad26.COV2.S, Biological: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Optimal Research, San Diego, California, United States

Brief Summary

The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort, in healthy adults aged greater than or equal to 18 to less than or equal to 55 years and in adults aged greater than or equal to 65 years in good health with or without stable underlying conditions.

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Breast Cancer
View Full Trial
INTERVENTION

Drug: Fulvestrant, Drug: Debio 1347

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorioal Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a medication or combination of medications. Therefore, the purpose of this study is to decide the best dose of the study drug, Debio 1347, that can be given in combination with the standard hormonal drug, fulvestrant. Debio 1347 and fulvestrant could shrink the cancer but it could also cause side effects. This study tells us about the side effects of these drugs when given in this new combination, and how often they occur.

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Secondary Myelofibrosis, Primary Myelofibrosis
View Full Trial
INTERVENTION

Procedure: Allogeneic Hematopoietic Stem Cell Transplantation, Drug: Fludarabine, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Drug: Melphalan, Other: Pharmacological Study, Drug: Ruxolitinib, Drug: Ruxolitinib Phosphate, Drug: Sirolimus, Drug: Tacrolimus

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Medical Center, Duarte, California, United States

Brief Summary

This pilot clinical trial studies the side effects and best dose of ruxolitinib phosphate when given together with chemotherapy before and after a donor stem cell transplant in treating patients with myelofibrosis. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with chemotherapy before and after a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient?s immune cells and help destroy any remaining cancer cells.